Cost Effectiveness of Lenalidomide in the Treatment of Transfusion-Dependent Myelodysplastic Syndromes in the United States
Cancer Control - United States
doi 10.1177/107327480601304s04
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2006
Authors
Publisher
SAGE Publications